Optimi Health Corp files with US SEC for IPO

Optimi Health Corp files with US SEC for IPO

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), a Canadian manufacturer of GMP psychedelic medicines, has filed with the U.S. Securities and Exchange Commission (SEC) to list its shares on a U.S. exchange. The move comes as the company continues to expand its reach and diversify its product portfolio, including the recent launch of its natural psilocybin capsules in Australia for the treatment of Treatment-Resistant Depression (TRD).

Optimi's filing with the SEC follows its successful introduction of MDMA sales in Australia for Post-Traumatic Stress Disorder (PTSD) in October 2024. The company's 5mg natural psilocybin capsules, manufactured in-house at its GMP-licensed facility in British Columbia, Canada, were approved for prescription use under Australia's Authorised Prescriber Scheme. This approval, along with the recent launch, underscores Optimi's commitment to providing scalable psychedelic treatments directly to clinics.

The initial shipment of 1,000 psilocybin capsules, each containing 5mg of standardized naturally-derived psilocybin, was exported to Australia after independent Certificate of Analysis (COA) testing confirmed compliance with Australia's Therapeutic Goods Administration (TGA) specifications. Mind Medicine Australia, Optimi's authorized commercial partner, will oversee distribution and patient coordination through Australia's network of clinics and hospitals.

Optimi's IPO filing marks a significant milestone in the company's growth strategy, as it seeks to raise capital to expand its operations and further develop its product pipeline. The company's vertically integrated process, from cultivation to encapsulation, ensures the highest quality standards and compliance with regulatory requirements.

For more information about Optimi Health Corp. and its products, please visit www.optimihealth.ca.

References:
[1] https://www.biospace.com/press-releases/optimi-health-announces-launch-of-psilocybin-capsules-in-australia-for-treatment-resistant-depression